Kornimate/medical-research-clean huggingface dataset:
generation of marfan syndrome and fontan cardiovascular models using patient-specific induced pluripotent stem cells

Conditions: Marfan's Syndrome

Summary: medical researchers of national heart centre singapore will carry out a state-of-the-art study that examines the possibility of changing patients' own cells into multi-functional and potent stem cells called ips cells. these ips cells can subsequently give rise to functional cardiac cells (myocytes) and other cardiovascular cells which might give further clues into the manifestation of the structural heart disease. this study involves blood sample collection for pre-screening and skin biopsies to establish skin cell culture.

participants are invited to participate in this study because they have been diagnosed with marfan's syndrome whereby a gene mutation is suspected to have affected major blood vessel of their heart or have a fontan procedure that was carried out to re-direct blood flow in their heart. this study will recruit 30 subjects from national heart centre singapore over a period of 1 year. for clinically diagnosed marfan disease, a genetic test in a gene called fbn1 will be carried out to confirm the presence of gene mutation that is suspected to cause the disease. it is important for them to know that any research finding that indicates the presence of this gene mutation may only suggest a pre-disposition to marfan disease, but it does not definitely ascertain that gene has caused the disease or predict that they will develop the disease. further independent clinical genetic testing may be made available, should they so desire after consulting their doctor or genetic counsellor. the skin obtained during the course of this study will be used for this study only and will be stored and analysed for the purposes of this study only, for a period not exceeding 5 years for research studies and experimental transplant studies, and will be destroyed after completion of the study, unless they agree to donate the samples to national heart centre singapore for continuous storage for future studies that are approved by institutional review board. the blood will however be stored indefinitely in national heart centre for future research on molecular, imaging and outcome studies of cardiovascular health and disease.

Eligibility criteria:
inclusion criteria: * patient that are under the care of the cardiologist and diagnosed with marfan's syndrome or who had underwent fontan palliation exclusion criteria: * no

Keywords: fontan palliation marfan's syndrome
mindfulness meditation combined with progressive muscle relaxation training for uremic sarcopenia

Conditions: Hemodialysis Patients With Sarcopenia

Summary: to study the effect of mindfulness meditation combined with progressive muscle relaxation training on clinical efficacy and quality of life in maintenance hemodialysis (mhd) patients with sarcopenia. eligible sarcopenic patients in our hospital were randomly assigned to a control group (n = 24) and an intervention group (n = 25). the control group received conventional dialysis treatment, while the intervention group received mindfulness meditation combined with progressive muscle relaxation training during the interdialysis period in addition to conventional dialysis treatment. the effect of the intervention was evaluated after 12 weeks.to observe whether the combined intervention training can improve the motor ability and quality of life of patients with sarcopenia in a short period of time.


Eligibility criteria:
inclusion criteria: * patients who met the sarcopenia criteria established by the asian working group for sarcopenia (awgs) in 2014 * stable condition and generally good health status * good compliance and ability to collaborate well with the physician * undergoing hemodialysis three times per week for at least three months, with a kt/v ≥ 1.2 * no significant cardiovascular or cerebrovascular complications (such as severe heart failure, severe arrhythmias, angina, and cerebrovascular diseases) * patients with sarcopenia who met the clinical diagnostic criteria were selected to ensure the quality of the included patients exclusion criteria: * inability to complete handgrip strength, 6-meter walk test, 10 sit-to-stand tests, and the use of bioelectrical impedance analysis (bia) due to contraindications * coexistence of mental illness or severe cognitive or communication disorders

Keywords: mindfulness meditation progressive muscle relaxation uremic sarcopenia maintenance hemodialysis quality of life
bcrl prevention pilot

Conditions: Obesity; Breast Cancer

Summary: the purpose of this study is to establish feasiblity of recruiting obese breast cancer survivors at the end of treatment, getting those survivors to lose weight and attend follow-up visits for 6 months.

breast cancer related lymphedema occurs in 20-30% of survivors. weight loss could prevent onset. we seek to do a pilot study to establish feasibility of 1) recruiting survivors at risk for lymphedema to do a weight loss intervention, 2) achieving 10-15% weight loss over 26 weeks in this population, and 3) attendance at follow-up visits 6 months.

Eligibility criteria:
inclusion criteria: * women * breast cancer survivors who had 5 or more lymph nodes removed and radiation to lymph nodes as part of treatment. * completed all treatments - no metastatic cancers * overweight or obese (bmi greater than or equal to 25 kg/m2) * medically and logistically able to participate in a weight loss and exercise program over 6 months. * diagnosed with breast cancer within the past 2 years. exclusion criteria: * more than 2 years since breast cancer diagnosis * medical status that would preclude safety of participation in a weight loss and exercise program * metastatic cancer * already enrolled in a weight loss program

Keywords: obese women (bmi greater than or equal to 30), do not already have a diagnosis of lymphedema, who are done with surgery, chemotherapy, and radiation therapy, and who were diagnosed with breast cancer within the past 2 years will be invited to participate.
screening for lysosomal acid lipase deficiency

Conditions: Lysosomal Acid Lipase Deficiency

Summary: the primary outcome of this study is the development of a clinical profile of pediatric patients with lal-d, which will enable the sponsor to provide more focused guidance to the medical community as to which pediatric patients should be tested for lal-d.


Eligibility criteria:
inclusion criteria: 1. male or female patient is ≥ 2 to ≤ 16 years of age at the date of informed consent. (note: female patients who are of childbearing potential or are pregnant may participate in this study.) 2. patient or patient's parent or legal guardian (if applicable) consents to participation in the study. if the patient is of minor age, he/she is willing to provide assent where required per local regulations, and if deemed able to do so. 3. patient meets all components of criterion a and/or criterion b below. criterion a: patient has dyslipidemia, defined as having at least one of the following lipid abnormalities based on a local laboratory result obtained within 3 months prior to the date of informed consent (or at the screening visit, as applicable): ldl-c ≥ 130 mg/dl hdl c ≤ 40 mg/dl (male patients) or ≤ 50 mg/dl (female patients) note: for patients receiving a lipid-lowering medication (llm), the patient must have been on a stable dose of the llm for at least 4 weeks prior to the serum lipid result. and patient has at least one of the following liver or spleen abnormalities: hepatomegaly, as determined by the investigator based on a physical examination or imaging procedure; splenomegaly, as determined by the investigator based on a physical examination or imaging procedure; alt \>75 u/l or alt \>1.5x the upper limit of normal (uln) (based on age- and gender-specific normal ranges of the local laboratory performing the assay) within 3 months prior to the date of informed consent (or at the screening visit, as applicable). criterion b: patient has steatosis (microvesicular or mixed macro/microvesicular), hepatic fibrosis, and/or cirrhosis of unknown etiology, as determined from a liver biopsy performed within the previous 3 years. (note: for patients who have received a liver transplantation, the liver biopsy results must have been obtained prior to the date of the liver transplantation.) exclusion criteria: 1. patient has a confirmed cause of liver disease other than lal-d. 2. patient has genetically confirmed heterozygous familial hypercholesteremia or other secondary causes of hypercholesterolemia. 3. patient has current evidence of neurological dysfunction and/or a history of neurological dysfunction within one year prior to the date of informed consent. 4. patient has been previously screened for lal-d and found to have normal enzyme activity based on the reference range of the laboratory performing the assay. 5. patient is currently receiving treatment with sebelipase alfa (kanuma) or has previously participated in a clinical study with sebelipase alfa (kanuma).

Keywords: screening hepatic injury pediatric patients
impact of a sexology consultation on disease control of type 2 male diabetics with erectile dysfunction

Conditions: Erectile Dysfunction; Type 2 Diabetes

Summary: erection disorders constitute the first sign of vascular injury in type 2 diabetes patients. the important frequency of these disorders and their consequences in term of quality of life have a strong contrast with the actual interest showed for them by the medical community. natural evolution of the disease and its management make that these disorders often occur little time after a therapeutic change. as a consequence, patients often accuse their medication to be responsible for the appearance of these disorders. this confusion, associated to false believes that may have the patients on their disease or their treatment, often leads to treatment discontinuation which has a deleterious effect on the disease evolution. educational therapy programs showed a positive impact on therapeutic adherence. increasing patients' knowledge on their disease and treatments increases their therapeutic adherence and makes it easier to balance diabetes and therefore limits complications appearance. educational therapy programs concern today the disease, its process, its evolution, its treatments, their efficacy, their adverse effects but erection disorders are not specifically addressed. this study aims to evaluate the impact of a sexology consultation on diabetes balance measured via hba1c rate. this consultation aims at precising this particular symptom of erection disorders, without any medicine prescription. the aim is to explain to patients the different links between their symptoms, diabetes, medicines and themselves.


Eligibility criteria:
inclusion criteria: * type 2 diabetic male medically treated * aged from 18 to 65 years old included * having issue obtaining or maintaining an erection allowing a satisfying sexual intercourse * hospitalised or followed in consultation in one of the 2 participating sites exclusion criteria: * treated by a medicine which could be responsible for the erectile disorders (beta-blockers, central anti-hypertensive drugs, antialdosterones) * presenting another disease which could be responsible for the erectile disorders (neurological, hormonal, vascular, psychiatric diseases) * treated by an insulin pump
acute decompensation of pulmonary hypertension

Conditions: Hypertension, Pulmonary; Biomarkers

Summary: the main objective of this study is to analyze the survival of a cohort of patients admitted for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary hypertension and to establish the prognostic value of biomarkers.

it is planned to include 150 patients over a two-year period. the primary endpoint is a composite endpoint including death, circulatory assistance or emergency transplantation within 90 days following admission to intensive care unit. patients will be treated according to the usual practice. a biobank will be created from blood samples taken at admission, days 3 and days 7. prognostic value of pre-selected biomarkers will be analyzed and a proteomic analysis will be performed in order to identify new biomarkers. the prognostic value of these new biological parameters will be compared to the usual monitoring parameters that will be collected during follow-up (clinical, echocardiographic and haemodynamic parameters). in a second step, it will establish, using a dynamic model, the best combinations of parameters allowing to best assessment of prognosis of patients suffering from ph and hospitalized for acute right ventricular failure.

Eligibility criteria:
inclusion criteria: * adult patients over 18 years * diagnosis of pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study * patients admitted in intensive care unit for acute decompensation of pulmonary hypertension requiring intravenous diuretic therapy ± use of inotropes or vasopressors. * patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures exclusion criteria: * patients with post-capillary pulmonary hypertension * patients with pulmonary hypertension associated with chronic respiratory disease * patients with pulmonary hypertension with unclear/or multifactorial mechanisms * patients with operable chronic thromboembolic pulmonary hypertension * shock due to another cause than acute decompensation of pulmonary hypertension * pregnant women, or breast feeding women * adult protected person * person deprived of liberty * person admitted without consent * pregnant or breastfeeding women
inverted internal limiting membrane flap technique for macular hole retinal detachment in highly myopic eyes

Conditions: Macular Hole Retinal Detachment

Summary: to evaluate efficacy of vitrectomy with inverted internal limiting membrane (ilm) flap technique for macular hole retinal detachment (mhrd) in highly myopic eyes, and to demonstrate postoperative clinical course of mhrd after inverted ilm flap technique using swept-source optical coherence tomography (oct)

macular hole retinal detachment (mhrd) threatens a certain number of highly myopic patients for irreversible visual dysfunction, and mostly requires immediate surgical intervention. the aim of they study is to evaluate efficacy of vitrectomy with inverted internal limiting membrane (ilm) flap technique for mhrd in highly myopic eyes, and to demonstrate postoperative clinical course of mhrd after inverted ilm flap technique using swept-source optical coherence tomography.

Eligibility criteria:
inclusion criteria: * the inclusion criteria were patients who underwent vitrectomy and internal limiting membrane removal or inverted for macular hole retinal detachment and had followed for more than 6 months. exclusion criteria: * the patients with follow-up less than 6 months.

Keywords: vitrectomy macular hole retinal detachment high myopia
role of high frequency rtms in management of opioid use disorder

Conditions: Addiction; Opioid; RTMS

Summary: this study aims to evaluate the role of repetitive transcranial magnetic stimulation (rtms) applied to the left dorsolateral prefrontal cortex (dlpfc) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with opioid use disorder, while also evaluating associated factors.

addiction is a complex, chronic brain condition influenced by genes and the environment that is characterized by substance use or compulsive actions that continue despite harmful consequences. for a long time, addiction meant an uncontrollable habit of using alcohol or other drugs as opioid. more recently, the concept of addiction has expanded to include behaviors, as well as substances, and even ordinary and necessary activities, such as exercise and eating. speaking of opioid addiction, opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. some other opioids, such as heroin, are illegal drugs of abuse. opioid addiction is characterized by a powerful, compulsive urge to use opioid drugs, even when they are no longer required medically. opioids have a high potential for causing addiction in some people, even when the medications are prescribed appropriately and taken as directed. many prescription opioids are misused or diverted to others. individuals who become addicted may prioritize getting and using these drugs over other activities in their lives, often negatively impacting their professional and personal relationships. it is unknown why some people are more likely to become addicted than others.

Eligibility criteria:
inclusion criteria: * male * age 18- 40 * opioid use disorder exclusion criteria: * individuals with mental disorders (such as primary psychosis, schizophrenia, mental retardation, and brain damage induced mental disorder), * history of epilepsy * history of cardiovascular complications. * history of contraindications to tms (e.g. metal implants in the head).

Keywords: addiction opioid rtms egypt
native tissue repair in pelvic organ prolapse -long-term results and risk of re-operation

Conditions: Pelvic Organ Prolapse; Cystocele

Summary: this study evaluates the recurrence of pelvic organ prolapse and the rate of re-operation after primary surgery for anterior vaginal wall prolapse with native tissue repair in long term follow-up.

this was a retrospective cohort study including patients undergoing their first surgical intervention for pelvic organ prolapse in turku university hospital gynecology department in the years 2000-2005. the point of interest was to study patients with prolapse of the anterior vaginal compartment (i.e. cystocele) with native tissue repair surgical approach as treatment. we made a search from the medical database of surgical procedures for operation codes lef00 (i.e.anterior colporraphy and lef13 (i.e. vaginal hysterectomy of descended uterus with/without vaginal/perineal molding) during the studied period. initially, we found 699 patients with matching operating codes and for those, we went through their medical records. from the final study population, we excluded those who had previously had an operation for pelvic organ prolapse and those whose primary operation didn't include anterior colporraphy and those who weren't eligible for long term follow-up. thus, the study population constituted of 392 subjects who were followed through medical records until the end of october 2018. from the medical records, we collected the day of birth, the date of the primary operation, body mass index, history of vaginal childbirth and cesarean section (if available), history of incontinence surgery, the grade of cystocele and diagnosis and before surgery, the operation code and executed surgical procedures, possible complications, and the history of possible re-operations. also, the date of death was reported as well as the date of changing residence outside the hospital district of varsinais-suomi. all gathered information were saved without personal details.

Eligibility criteria:
inclusion criteria: * cystocele treated with native tissue surgery, medical records reaching until the end of follow-up period exclusion criteria: * history of previous pelvic organ prolapse surgery

Keywords: recurrence native tissue repair
caregiver burden, effectiveness and other health care measures on functional disability, in patients treated with abobotulinumtoxin a for upper limb spasticity

Conditions: Upper Limb Injury

Summary: the aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of abobont-a on caregiver burden, functional disability and other health care measures in patients affected with uls due to acquired brain injuries.


Eligibility criteria:
inclusion criteria: 1. the patient is able to comply with the protocol; 2. male and female patients who are at least 18 years old; 3. the patient is supported by an identified caregiver (family member or other nonpaid adult - if the patient has more than one caregiver, the main caregiver will be selected) who provides daily supervision or direct assistance to the care recipient; 4. the patient has been diagnosed with uls due to non-progressive acquired brain injuries (stroke, traumatic brain injury, surgical resection of non-progressive tumours, other) or due to non-progressive spinal cord injury with stability of spasticity of the upper limbs; 5. the decision to treat the patient with abobont-a by the care provider will be made prior to, and independently from the decision to enrol the patient in the observational study; 6. the patient is covered by a healthcare insurance; 7. the cognitive and health status of the patient is compatible with the participation to the study. for caregivers : (8) the caregiver is able to comply with the protocol; (9) male and female caregivers who are at least 18 years old; (10) the cognitive and health status of the caregiver is compatible with the participation to the study. exclusion criteria: 1. contraindication to bont-a treatment; 2. previously treated with bont-a in upper limbs within the last 12 months; 3. patients and if applicable legally authorized representative (lar) of patient under curatorship or deprived of liberty who are opposed to their data collection 4. caregivers who are opposed to their data collection; 5. caregivers already included for another patient; 6. current participation in any other interventional clinical study or have participated within the 12 weeks prior to the inclusion visit; 7. non-ambulatory patients except for those who have been hospitalized for the purpose of their bont-a injection (maximum length of stay as per clinical judgment of the investigator); 8. vulnerable patients (i.e. pregnant and/or lactating women, children, patient under curatorship or deprived of liberty).